ArticleJournal of fungi (Basel, Switzerland)2021
In Vitro Antifungal Drug Resistance Profiles of Clinically Relevant Members of the Mucorales (Mucoromycota) Especially with the Newer Triazoles.
Article in Journal of fungi (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Pooled it
- Biomarkers in Invasive Pulmonary Fungal Infections: Where Do We Stand?Journal of fungi (Basel, Switzerland) · 2026Review
- Understanding the biology of mucormycosis using contemporary omics tools: a review.Biotechnologia · 2026Review
- Pediatric Fungal Keratitis: Predisposing Factors, Clinical Features, and Outcomes During a 24-Year Study.Translational vision science & technology · 2025Article
- Non-JHLT open · 2025Review
- Mucormycosis.Infectious disease clinics of North America · 2025Review
- Invasive Mucormycosis in a Chronic Lymphocytic Leukemia Patient on Zanubrutinib: A Case Report.Infection and drug resistance · 2025Article
- Article
- Molecular mechanisms that govern infection and antifungal resistance in Mucorales.Microbiology and molecular biology reviews : MMBR · 2024Review
- Antifungal susceptibility profiles for fungal isolates from corneas and contact lenses in the United Kingdom.Eye (London, England) · 2024Article
- Trans-kingdom fungal pathogens infecting both plants and humans, and the problem of azole fungicide resistance.Frontiers in microbiology · 2024Review
- A rare intestinal mucormycosis caused byFrontiers in medicine · 2024Article
- Changes in fungal taxonomy: mycological rationale and clinical implications.Clinical microbiology reviews · 2023Review
- Article
- Mucormycosis in a Severe Trauma Patient Treated with a Combination of Systemic Posaconazole and Topical Amphotericin B-Case Report.Antibiotics (Basel, Switzerland) · 2023Article
- In Vitro Activity of Isavuconazole and Amphotericin B in Association against Mucorales.Pathogens (Basel, Switzerland) · 2023Article
- Epidemiology, Modern Diagnostics, and the Management of Mucorales Infections.Journal of fungi (Basel, Switzerland) · 2023Review
- Combination therapy in Mucormycosis: Current evidence from the world literature, a mini review.Journal de mycologie medicale · 2023Review
- Antifungal Activity of Isavuconazole and Comparator Agents against Contemporaneous Mucorales Isolates from USA, Europe, and Asia-Pacific.Journal of fungi (Basel, Switzerland) · 2023Article
- Promising Antifungal Molecules against Mucormycosis Agents Identified from Pandemic Response BoxJournal of fungi (Basel, Switzerland) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Mucoromycoses (infections caused by members of the order Mucorales, phylum Mucoromycota [ex-Zygomycota]) are highly destructive, rapidly progressive infections, with dire prognoses especially when they occur in immunocompromised hosts. Current treatment guidelines recommend liposomal formulations of amphotericin B with adjunctive surgery as first line therapy, with the newer triazoles posaconazole or isavuconazole as alternative treatments, or as salvage therapy. Among the many organisms belonging to this order, a limited number of species in the genera
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.